1. Therapeutic drug monitoring (TDM) is routinely used for ethosuximide in childhood absence epilepsy. Which plasma concentration range defines the established therapeutic window for ethosuximide?
A) 10–20 mcg/mL, the same therapeutic range used for phenytoin, reflecting the shared sodium channel mechanism between these two anti-seizure drugs
B) 20–40 mcg/mL, a relatively narrow window that requires frequent monitoring because the gap between therapeutic and toxic concentrations is small for this agent
C) 40–100 mcg/mL, a range supported by clinical correlation data linking concentrations in this window to seizure suppression while avoiding concentration-dependent adverse effects such as nausea and CNS toxicity
D) 150–250 mcg/mL, a high-concentration range necessary because ethosuximide's low protein binding means a large proportion of administered drug is rapidly filtered by the kidneys before reaching therapeutic tissue concentrations
E) 5–15 mcg/mL, a low-concentration range that reflects ethosuximide's high potency at T-type calcium channels, where nanomolar receptor occupancy is sufficient for full therapeutic effect
ANSWER: C
Rationale:
The established therapeutic plasma concentration range for ethosuximide is 40–100 mcg/mL, derived from clinical pharmacokinetic studies correlating drug concentrations with seizure control and adverse effect emergence. Ethosuximide has low protein binding (less than 10%), so total plasma concentrations reliably reflect free drug exposure without the correction needed for highly protein-bound drugs such as phenytoin or valproate. Concentrations below 40 mcg/mL are associated with inadequate seizure control in many patients, while concentrations above 100 mcg/mL are associated with increasing rates of gastrointestinal and CNS adverse effects. This range guides initial dose titration and adjustments during intercurrent illness or drug interactions.
Option A: Option A is incorrect because the 10–20 mcg/mL therapeutic range is specific to phenytoin, which has a completely different mechanism (sodium channel fast inactivation) and different pharmacokinetic characteristics from ethosuximide; ethosuximide's therapeutic range is substantially higher at 40–100 mcg/mL.
Option B: Option B is incorrect because 20–40 mcg/mL falls below the established therapeutic range for ethosuximide; concentrations in this range are typically sub-therapeutic and associated with inadequate absence seizure control in most patients.
Option D: Option D is incorrect because 150–250 mcg/mL substantially exceeds the established therapeutic range for ethosuximide and would represent toxic concentrations; low protein binding does not require a higher therapeutic range — rather, it simplifies TDM by making total concentration a reliable surrogate for free drug.
Option E: Option E is incorrect because 5–15 mcg/mL is far below the established therapeutic range for ethosuximide; this range is not clinically relevant for ethosuximide and the premise that nanomolar receptor occupancy drives efficacy is not consistent with ethosuximide's pharmacodynamic profile.
2. Brivaracetam's elimination half-life has direct implications for its dosing schedule. What is brivaracetam's elimination half-life and what dosing frequency does it require?
A) Brivaracetam has an elimination half-life of approximately 7 to 8 hours, which supports twice-daily dosing to maintain stable plasma concentrations throughout the day
B) Brivaracetam has an elimination half-life of approximately 20 to 24 hours, which allows once-daily dosing and is one of its primary pharmacokinetic advantages over levetiracetam's shorter half-life requiring twice-daily dosing
C) Brivaracetam has an elimination half-life of approximately 3 to 4 hours, necessitating three-times-daily dosing for consistent plasma levels, though extended-release formulations allow twice-daily dosing in clinical practice
D) Brivaracetam has an elimination half-life of approximately 70 to 110 hours, the same as perampanel, because both drugs are metabolized by CYP3A4 at similar rates and share comparable lipophilicity
E) Brivaracetam has an elimination half-life of approximately 40 to 60 hours, equivalent to ethosuximide, because both drugs are eliminated primarily by hepatic hydroxylation to inactive metabolites with similar clearance rates
ANSWER: A
Rationale:
Brivaracetam has an elimination half-life of approximately 7 to 8 hours, which is similar to levetiracetam's half-life of 6 to 8 hours. This half-life supports twice-daily dosing for both agents. The two drugs therefore share the same dosing frequency, and the pharmacokinetic rationale for preferring brivaracetam over levetiracetam lies in its higher SV2A binding affinity, faster brain penetration, and more favorable psychiatric adverse effect profile — not in a dosing schedule advantage. Brivaracetam reaches peak plasma concentrations within approximately 1 hour of oral dosing and has bioavailability exceeding 95%.
Option B: Option B is incorrect because brivaracetam does not have a 20 to 24-hour half-life; a half-life in that range would support once-daily dosing, but brivaracetam's actual half-life of 7 to 8 hours requires twice-daily dosing, which is the same schedule as levetiracetam.
Option C: Option C is incorrect because brivaracetam's half-life is approximately 7 to 8 hours, not 3 to 4 hours; a half-life of 3 to 4 hours would require more frequent dosing than twice-daily, and there is no extended-release formulation of brivaracetam in clinical use.
Option D: Option D is incorrect because brivaracetam's half-life of 7 to 8 hours is entirely different from perampanel's 70 to 110 hours; the two drugs have markedly different metabolic pathways — brivaracetam is metabolized primarily by amidase hydrolysis, while perampanel is metabolized by CYP3A4 — and their half-lives reflect these differences.
Option E: Option E is incorrect because ethosuximide has a half-life of 40 to 60 hours in adults, which is orders of magnitude longer than brivaracetam's 7 to 8 hours; the two drugs have completely different metabolic pathways and clearance rates.
3. The mandatory slow titration schedule for cenobamate was established after four cases of DRESS occurred with rapid titration in early clinical trials. Which titration schedule is required when initiating cenobamate?
A) Cenobamate must be started at 50 mg/day for 4 weeks, then increased by 50 mg every 4 weeks, reaching a maximum of 400 mg/day after approximately 7 months of titration
B) Cenobamate must be started at 25 mg/day for 4 weeks, then increased by 50 mg every 2 weeks, reaching the target maintenance dose of 200 to 400 mg/day after approximately 3 months
C) Cenobamate must be started at 6.25 mg/day for 4 weeks, then doubled every 4 weeks, with the entire titration phase taking a minimum of 6 months before the target dose is reached
D) Cenobamate must be started at 100 mg/day for 2 weeks to establish tolerability, then reduced to 50 mg/day for 2 weeks if well-tolerated, before increasing gradually to the maintenance dose range
E) Cenobamate must be started at 12.5 mg/day for 2 weeks, then increased to 25 mg/day for 2 weeks, then increased by 25 mg every 2 weeks thereafter as tolerated toward the target maintenance dose of 200 to 400 mg/day
ANSWER: E
Rationale:
The mandatory cenobamate titration schedule is: 12.5 mg/day for weeks 1 and 2, then 25 mg/day for weeks 3 and 4, then increases of 25 mg every 2 weeks thereafter as tolerated, targeting a maintenance dose of 200 to 400 mg/day. This specific schedule was implemented after the four DRESS cases that occurred with rapid titration over 1 to 2 weeks in the early clinical program. With this slow titration protocol in place, no additional DRESS cases occurred in over 1,900 subsequent patients. The schedule is non-negotiable and cannot be accelerated even in urgent circumstances — rapid titration is prohibited regardless of the clinical situation. Clinicians initiating cenobamate must be familiar with this exact schedule and must monitor patients for early signs of DRESS (fever, rash, lymphadenopathy, eosinophilia) throughout the titration period.
Option A: Option A is incorrect because the required starting dose is 12.5 mg/day, not 50 mg/day; starting at 50 mg/day would represent an inappropriately rapid initiation inconsistent with the DRESS-prevention protocol established in cenobamate's clinical program.
Option B: Option B is incorrect because the required starting dose is 12.5 mg/day, not 25 mg/day; the first step in the mandatory titration schedule begins at 12.5 mg/day for the first 2 weeks, and increments are 25 mg every 2 weeks rather than 50 mg every 2 weeks.
Option C: Option C is incorrect because the required starting dose is 12.5 mg/day, not 6.25 mg/day, and the approved titration schedule uses 25 mg increments every 2 weeks rather than a doubling schedule; the overall timeline to maintenance dose is also considerably shorter than 6 months with the approved protocol.
Option D: Option D is incorrect because the approved titration schedule begins at the lowest dose (12.5 mg/day) and increases progressively — it does not start at a higher load-then-reduce approach, which would defeat the purpose of the slow-titration DRESS-prevention protocol.
4. Which statement correctly describes perampanel's oral bioavailability and plasma protein binding?
A) Perampanel has oral bioavailability of approximately 60% due to moderate first-pass hepatic extraction, and protein binding of approximately 50%, placing it in an intermediate pharmacokinetic category among anti-seizure drugs
B) Perampanel has oral bioavailability of approximately 100% and is approximately 95% bound to plasma proteins, making it highly bioavailable after oral dosing while existing predominantly in the protein-bound (pharmacologically inactive) fraction in plasma
C) Perampanel has oral bioavailability of approximately 100% and very low protein binding of approximately 5%, so the vast majority of circulating perampanel is pharmacologically active free drug, explaining its high potency at low doses
D) Perampanel has oral bioavailability of approximately 40% due to extensive intestinal P-glycoprotein efflux, and protein binding exceeding 99%, making plasma concentration monitoring unreliable as a guide to free drug exposure
E) Perampanel has oral bioavailability of approximately 80% and protein binding of approximately 70%, a pharmacokinetic profile similar to carbamazepine that makes drug interaction monitoring important for both protein-displacement and metabolic interactions
ANSWER: B
Rationale:
Perampanel has nearly complete oral bioavailability of approximately 100%, meaning essentially the entire administered dose reaches systemic circulation. It is approximately 95% bound to plasma proteins. High protein binding means that the vast majority of circulating perampanel is in the bound (inactive) form at any given moment; only the free 5% fraction is pharmacologically active and available to cross the blood-brain barrier and bind AMPA receptors. While high protein binding can in principle create displacement interactions with other highly bound drugs, perampanel's primary clinically significant pharmacokinetic interactions are metabolic — CYP3A4 inducers reducing its concentrations — rather than protein-displacement interactions. These pharmacokinetic parameters, combined with its long half-life, make perampanel a highly predictable drug in terms of systemic exposure after oral dosing.
Option A: Option A is incorrect because perampanel's oral bioavailability is approximately 100%, not 60%; it does not undergo significant first-pass hepatic extraction. Protein binding is approximately 95%, not 50%.
Option C: Option C is incorrect because while perampanel's bioavailability of approximately 100% is correct, its protein binding is approximately 95%, not 5%; low protein binding is a characteristic of drugs such as gabapentin and levetiracetam, not perampanel.
Option D: Option D is incorrect because perampanel has high oral bioavailability of approximately 100%, not 40% due to P-gp efflux; P-glycoprotein-limited absorption is relevant for drugs such as certain antiepileptics but is not a significant pharmacokinetic characteristic of perampanel. Protein binding is approximately 95%, not exceeding 99%.
Option E: Option E is incorrect because perampanel's oral bioavailability is approximately 100%, not 80%, and its protein binding is approximately 95%, not 70%; carbamazepine's bioavailability and binding profile differ from perampanel's.
5. A clinical pharmacologist is reviewing drug interaction risk for a patient on gabapentin who is being started on valproate, a drug that is approximately 90% protein-bound. She concludes that protein-displacement interactions are not a concern with this combination. What pharmacokinetic property of gabapentin justifies this conclusion?
A) Gabapentin is also approximately 90% protein-bound, and because both drugs compete for the same albumin binding sites, displacement of one by the other results in proportional changes in both free fractions that cancel each other out and produce no net pharmacodynamic effect
B) Gabapentin is metabolized by the same CYP enzymes as valproate, so any increase in free gabapentin from protein displacement would be offset by accelerated CYP-mediated clearance, maintaining stable free drug concentrations despite the interaction
C) Gabapentin is a large, polar molecule that binds exclusively to alpha-1-acid glycoprotein rather than albumin; since valproate binds only to albumin, the two drugs occupy entirely separate protein binding sites and cannot displace each other
D) Gabapentin has negligible plasma protein binding of less than 3%, so essentially all circulating gabapentin is already in the free (unbound) form; there is no meaningful protein-bound fraction that could be displaced by valproate or any other drug
E) Gabapentin is eliminated by renal excretion so rapidly that its plasma half-life is shorter than the time required for protein-displacement equilibrium to shift, making displacement interactions kinetically impossible regardless of protein binding status
ANSWER: D
Rationale:
Gabapentin has very low plasma protein binding of less than 3%, meaning that essentially all circulating gabapentin exists as free, unbound drug in plasma. Because there is no meaningful protein-bound reservoir to displace, protein-displacement interactions are pharmacokinetically irrelevant for gabapentin regardless of what other highly protein-bound drugs are co-administered. This is a genuine pharmacokinetic advantage — gabapentin's low protein binding, combined with absence of hepatic metabolism and lack of CYP interactions, gives it one of the cleanest drug interaction profiles among anti-seizure drugs. Pregabalin shares this characteristic, with similarly negligible protein binding.
Option A: Option A is incorrect because gabapentin is not approximately 90% protein-bound; its protein binding is less than 3%. The premise of the option — that matching protein binding percentages cancel displacement effects — is also pharmacokinetically unsound.
Option B: Option B is incorrect because gabapentin is not hepatically metabolized by CYP enzymes; it is eliminated renally unchanged and has no CYP-mediated metabolic pathway. Accelerated CYP clearance cannot compensate for protein displacement because no such pathway exists for gabapentin.
Option C: Option C is incorrect because gabapentin does not bind selectively to alpha-1-acid glycoprotein while excluding albumin binding; gabapentin's low protein binding of less than 3% reflects minimal binding to any plasma protein. The premise of selective glycoprotein binding is not an established pharmacokinetic characteristic of gabapentin.
Option E: Option E is incorrect because gabapentin's elimination half-life is approximately 5 to 7 hours in patients with normal renal function, which is not so brief as to make protein-displacement kinetics impossible; the real reason displacement interactions are irrelevant is the minimal protein binding, not the elimination rate.
6. Ethosuximide's elimination half-life differs between adults and children, with practical implications for dosing frequency and time to steady state. Which values correctly describe ethosuximide's half-life in each population?
A) Ethosuximide has a half-life of approximately 6 to 8 hours in both adults and children, requiring three-times-daily dosing in all age groups to maintain stable plasma concentrations above the minimum therapeutic threshold
B) Ethosuximide has a half-life of approximately 20 to 30 hours in adults and 10 to 15 hours in children, reflecting age-related differences in CYP3A4 expression that result in faster clearance in children compared to adults
C) Ethosuximide has an elimination half-life of approximately 40 to 60 hours in adults and approximately 30 to 40 hours in children, allowing once-daily or twice-daily dosing in both age groups and requiring approximately one week to reach steady state after a dose change
D) Ethosuximide has an elimination half-life of approximately 70 to 110 hours in adults and approximately 50 to 70 hours in children, similar to perampanel, because both drugs are lipophilic compounds eliminated by hepatic CYP3A4 with comparable intrinsic clearance rates
E) Ethosuximide has a half-life of approximately 12 to 18 hours in adults and approximately 8 to 12 hours in children, requiring twice-daily dosing in adults and three-times-daily dosing in children to achieve consistent therapeutic concentrations
ANSWER: C
Rationale:
Ethosuximide has an elimination half-life of approximately 40 to 60 hours in adults and approximately 30 to 40 hours in children. The shorter half-life in children reflects higher weight-normalized hepatic CYP3A4 metabolic capacity per kilogram in the pediatric population, consistent with the well-established principle that children often require higher weight-adjusted doses of hepatically metabolized drugs to achieve equivalent plasma concentrations. The long half-life in both age groups allows once-daily or twice-daily dosing while maintaining stable plasma concentrations. A half-life of 40 to 60 hours in adults means that steady state is reached after approximately 5 half-lives — roughly 8 to 12 days — following a dose change, which guides expectations for when therapeutic drug monitoring samples should be obtained after initiation or dose adjustment.
Option A: Option A is incorrect because ethosuximide's half-life is far longer than 6 to 8 hours; a half-life in that range would characterize drugs such as brivaracetam or levetiracetam, not ethosuximide. A 6 to 8-hour half-life would necessitate multiple daily doses, which is inconsistent with ethosuximide's established once- or twice-daily clinical dosing.
Option B: Option B is incorrect because ethosuximide's half-life in adults is approximately 40 to 60 hours, not 20 to 30 hours, and in children approximately 30 to 40 hours, not 10 to 15 hours; while children do have faster clearance than adults, the absolute half-life values stated in this option are significantly lower than established pharmacokinetic data.
Option D: Option D is incorrect because ethosuximide's half-life of 40 to 60 hours in adults, while long, is distinctly shorter than perampanel's 70 to 110 hours; the two drugs have different metabolic profiles and lipophilicity characteristics despite both being CYP3A4 substrates.
Option E: Option E is incorrect because the 12 to 18-hour range for adults and 8 to 12-hour range for children substantially underestimate ethosuximide's established pharmacokinetic parameters; half-lives in those ranges are characteristic of intermediate-acting drugs, not the long-acting ethosuximide.
7. Understanding brivaracetam's metabolic pathway is important for predicting drug interactions and managing patients with organ impairment. Which statement correctly describes how brivaracetam is primarily metabolized?
A) Brivaracetam is metabolized primarily by hydrolysis via amidase enzymes to an inactive carboxylic acid metabolite, with a minor secondary contribution from CYP2C19-mediated hydroxylation; this metabolic profile means hepatic rather than renal impairment requires dose adjustment
B) Brivaracetam is metabolized primarily by CYP3A4 to an active hydroxylated metabolite that contributes approximately 40% of the drug's total anti-seizure effect, and CYP3A4 inducers such as carbamazepine reduce both brivaracetam and its active metabolite concentrations substantially
C) Brivaracetam undergoes extensive renal tubular secretion as its primary elimination pathway and is excreted largely unchanged in the urine, so dose adjustment in renal impairment follows the same schedule as levetiracetam
D) Brivaracetam is metabolized primarily by CYP2D6 to an inactive sulfoxide metabolite; patients who are CYP2D6 poor metabolizers require dose reduction of approximately 50% to avoid accumulation to toxic concentrations
E) Brivaracetam undergoes glucuronidation by UGT1A9 as its primary metabolic pathway, making it susceptible to interactions with UGT inducers such as rifampin and UGT inhibitors such as valproate, which can alter brivaracetam exposure by 30 to 50%
ANSWER: A
Rationale:
Brivaracetam's primary metabolic pathway is hydrolysis mediated by amidase enzymes, which convert it to an inactive carboxylic acid metabolite. A secondary pathway involves CYP2C19-mediated hydroxylation. Neither pathway involves CYP3A4 as a primary route, which distinguishes brivaracetam from perampanel (a CYP3A4 substrate) and means that the potent CYP3A4 inducers carbamazepine and phenytoin do not substantially reduce brivaracetam levels through this mechanism (though rifampin, a broad inducer, does reduce exposure). Because hepatic metabolism is the primary clearance pathway, dose adjustment is required in moderate to severe hepatic impairment — not for renal impairment, which is the key practical distinction from levetiracetam.
Option B: Option B is incorrect because brivaracetam is not a CYP3A4 substrate and is not converted to a pharmacologically active metabolite; its primary pathway is amidase-mediated hydrolysis to an inactive carboxylic acid, and the drug is not a prodrug requiring metabolic activation.
Option C: Option C is incorrect because brivaracetam is not eliminated primarily by renal tubular secretion unchanged; unlike levetiracetam, which is renally eliminated, brivaracetam undergoes hepatic amidase-mediated metabolism, and dose adjustment follows hepatic (not renal) impairment criteria.
Option D: Option D is incorrect because CYP2D6 is not the primary metabolic pathway for brivaracetam; the primary pathway is amidase hydrolysis, with CYP2C19 as a secondary contributor. CYP2D6 poor metabolizer status is not a clinically established dosing consideration for brivaracetam.
Option E: Option E is incorrect because UGT1A9-mediated glucuronidation is not brivaracetam's primary metabolic route; glucuronidation is the primary pathway for drugs such as lamotrigine (UGT1A4) and certain other anti-seizure agents, not brivaracetam.
8. Cenobamate has a complex drug interaction profile involving multiple CYP enzyme pathways. At therapeutic doses, what is cenobamate's net effect on CYP3A4 activity, and what is a clinically important consequence of this effect?
A) Cenobamate inhibits CYP3A4 at all therapeutic doses, increasing plasma concentrations of CYP3A4 substrates; the most important clinical consequence is a rise in carbamazepine parent drug levels requiring a carbamazepine dose reduction when cenobamate is added
B) Cenobamate has no effect on CYP3A4 at any dose; its drug interactions are mediated exclusively through CYP2C19 inhibition at lower doses and CYP2C19 induction at higher doses, with CYP3A4 substrates unaffected throughout the therapeutic range
C) Cenobamate inhibits CYP3A4 at low doses and induces CYP3A4 at doses above approximately 200 mg/day, with the net effect at most therapeutic doses being moderate inhibition; carbamazepine levels therefore rise in most patients on cenobamate
D) Cenobamate is a potent irreversible CYP3A4 inhibitor that permanently reduces CYP3A4 activity; enzyme recovery after cenobamate discontinuation requires new enzyme synthesis over 2 to 4 weeks, during which CYP3A4 substrate concentrations remain elevated
E) Cenobamate induces CYP3A4 at therapeutic doses, reducing plasma concentrations of CYP3A4 substrates; carbamazepine is a CYP3A4 substrate and its levels may fall when cenobamate is added, potentially reducing seizure control if the carbamazepine dose is not increased
ANSWER: E
Rationale:
Cenobamate induces CYP3A4 at therapeutic doses. CYP3A4 induction increases the metabolic clearance of CYP3A4 substrates, reducing their plasma concentrations. Carbamazepine is metabolized in part by CYP3A4, so its levels can decrease when cenobamate is added to an existing carbamazepine regimen — potentially reducing carbamazepine efficacy if the dose is not adjusted upward. This is distinct from cenobamate's concurrent CYP2C19 effects: at lower doses cenobamate acts primarily as a CYP2C19 inhibitor (causing phenytoin accumulation), while at higher doses CYP2C19 induction becomes the dominant effect. The practical management of cenobamate's interaction burden requires reviewing all co-medications for both CYP2C19 and CYP3A4 pathways before initiating.
Option A: Option A is incorrect because cenobamate induces rather than inhibits CYP3A4 at therapeutic doses; inhibition of CYP3A4 would raise carbamazepine levels, but the actual effect is induction reducing CYP3A4 substrate levels.
Option B: Option B is incorrect because cenobamate does affect CYP3A4 — it is a CYP3A4 inducer at therapeutic doses in addition to its CYP2C19 effects; stating that CYP3A4 substrates are unaffected misrepresents cenobamate's interaction profile and could lead to clinically significant errors.
Option C: Option C is incorrect because it reverses the dose-dependent CYP effect: the established profile is CYP2C19 inhibition at lower doses transitioning toward induction at higher doses, while CYP3A4 induction is the effect at therapeutic doses — not CYP3A4 inhibition at low doses.
Option D: Option D is incorrect because cenobamate is not an irreversible CYP3A4 inhibitor; it is a CYP3A4 inducer, which means it increases enzyme synthesis rather than permanently destroying enzyme activity. Irreversible enzyme inhibition with prolonged recovery is the mechanism of drugs such as erythromycin in certain contexts or mechanism-based inhibitors, not cenobamate.
9. A clinician increases a patient's perampanel dose from 4 mg to 6 mg at bedtime and asks when a follow-up plasma level should be obtained to assess the new steady-state concentration. What is the correct answer, and what pharmacokinetic principle explains it?
A) A follow-up level should be obtained 48 hours after the dose increase, because perampanel's once-daily dosing means plasma concentrations equilibrate rapidly within 2 dosing intervals, after which the new steady state is fully established
B) A follow-up level should be obtained 2 to 3 weeks after the dose increase, because steady state requires approximately 5 half-lives to be achieved, and perampanel's half-life of 70 to 110 hours means that 5 half-lives spans approximately 14 to 23 days
C) A follow-up level should be obtained 3 to 4 days after the dose increase, because perampanel undergoes rapid distribution into the central nervous system that is complete within 72 hours, after which plasma and CNS concentrations equilibrate at the new steady state
D) A follow-up level should be obtained immediately before the next dose (trough level at 24 hours), because perampanel's linear pharmacokinetics mean that trough concentrations accurately predict steady-state exposure within one dosing interval
E) A follow-up level should be obtained 6 to 8 weeks after the dose increase, because perampanel's high protein binding of approximately 95% means that the drug distributes slowly into deep tissue compartments that take up to 2 months to fully equilibrate after a dose change
ANSWER: B
Rationale:
Steady-state plasma concentrations are reached after approximately 5 half-lives following a dose change. Perampanel's elimination half-life is approximately 70 to 110 hours. Multiplying 5 × 70 hours gives approximately 350 hours (approximately 14.6 days), and 5 × 110 hours gives approximately 550 hours (approximately 23 days). Therefore, steady state is not achieved until approximately 2 to 3 weeks after a dose change. This is a clinically important implication of perampanel's long half-life: clinicians who assess response or obtain plasma levels too soon after a dose adjustment will be measuring concentrations that have not yet reached steady state, potentially leading to premature further dose changes. Conversely, if adverse behavioral effects emerge after a dose increase, they may also persist for 2 to 3 weeks even if the dose is reduced.
Option A: Option A is incorrect because 48 hours is far too soon to assess perampanel's steady state; with a half-life of 70 to 110 hours, only 1 to 2 half-lives would have elapsed in 48 hours, meaning concentrations would still be accumulating substantially and would not represent the new steady state.
Option C: Option C is incorrect because 3 to 4 days represents approximately 1 to 1.4 half-lives (using the lower end of perampanel's half-life range), which is far too early to reach steady state; CNS distribution equilibration is not the rate-limiting step for perampanel's pharmacokinetic steady state.
Option D: Option D is incorrect because a trough level at 24 hours after a dose change reflects only one dosing interval of accumulation, not steady state; with a half-life of 70 to 110 hours, plasma concentrations will continue to accumulate for 2 to 3 weeks, and a 24-hour trough dramatically underestimates the eventual steady-state concentration.
Option E: Option E is incorrect because 6 to 8 weeks substantially overestimates the time to steady state; at 5 half-lives (2 to 3 weeks) the drug has reached greater than 97% of its final steady-state concentration, and high protein binding does not create a separately accumulating deep tissue compartment that delays steady state for months.
10. Which of the following lists correctly identifies FDA-approved indications for pregabalin in the United States?
A) Pregabalin is approved for generalized anxiety disorder, bipolar depression as adjunctive therapy, neuropathic pain from diabetic peripheral neuropathy, and post-herpetic neuralgia — reflecting its broad activity across both GABAergic and voltage-gated calcium channel pathways
B) Pregabalin is approved exclusively for neuropathic pain conditions — diabetic peripheral neuropathy, post-herpetic neuralgia, and central neuropathic pain from spinal cord injury — and carries no anti-seizure indication in any age group or seizure type
C) Pregabalin is approved for focal onset seizures as monotherapy in adults, neuropathic pain from diabetic peripheral neuropathy, fibromyalgia, and generalized anxiety disorder, but is not approved for post-herpetic neuralgia because lamotrigine is the preferred agent for that indication
D) Pregabalin is approved for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, spinal cord injury pain, and as adjunctive therapy for focal onset seizures; it is not approved for generalized epilepsy syndromes
E) Pregabalin is approved for all forms of neuropathic pain regardless of etiology, as well as first-line monotherapy for both focal and generalized epilepsy, making it the broadest-spectrum alpha-2-delta agent approved for neurological conditions
ANSWER: D
Rationale:
Pregabalin's FDA-approved indications include: neuropathic pain associated with diabetic peripheral neuropathy (DPN), post-herpetic neuralgia (PHN), fibromyalgia, neuropathic pain associated with spinal cord injury, and adjunctive therapy for focal onset seizures in adults and pediatric patients aged 1 month and older. It is not approved for generalized epilepsy syndromes — its anti-seizure efficacy is limited to focal onset seizures as adjunctive therapy, consistent with its mechanism of reducing presynaptic calcium influx via alpha-2-delta subunit binding, which does not translate to efficacy in generalized epilepsy. In Europe, pregabalin also carries an indication for generalized anxiety disorder, but this approval has not been granted by the FDA in the United States.
Option A: Option A is incorrect because pregabalin does not have FDA approval for generalized anxiety disorder in the United States (only in Europe) or for bipolar depression; the statement also incorrectly attributes a GABAergic mechanism to pregabalin, which acts at the alpha-2-delta subunit of voltage-gated calcium channels, not GABA receptors.
Option B: Option B is incorrect because pregabalin does carry an anti-seizure indication in the United States — adjunctive therapy for focal onset seizures — in addition to its pain indications; the statement incorrectly states it carries no anti-seizure indication.
Option C: Option C is incorrect because pregabalin is not approved as monotherapy for focal onset seizures — its anti-seizure indication is adjunctive therapy only — and lamotrigine is not the preferred agent for post-herpetic neuralgia; pregabalin and gabapentin are among the first-line agents for PHN.
Option E: Option E is incorrect because pregabalin's anti-seizure indication is limited to adjunctive therapy for focal onset seizures, not first-line monotherapy for any epilepsy type; it has no approved indication for generalized epilepsy syndromes, and its approval does not extend to all forms of neuropathic pain regardless of etiology.
11. Ethosuximide's volume of distribution has implications for its pharmacokinetic behavior and for therapeutic drug monitoring. Which value correctly describes ethosuximide's volume of distribution, and what does this value indicate about its distribution characteristics?
A) Ethosuximide has a volume of distribution of approximately 0.1 L/kg, indicating confinement largely to the plasma compartment due to high protein binding and limited tissue penetration, which is why total plasma concentrations reliably reflect active drug exposure
B) Ethosuximide has a volume of distribution of approximately 5 to 10 L/kg, indicating extensive tissue sequestration in lipophilic compartments including adipose tissue and the CNS, which prolongs its effective duration of action beyond what its plasma half-life would predict
C) Ethosuximide has a volume of distribution of approximately 0.7 L/kg, consistent with distribution throughout total body water, reflecting its low protein binding and moderate polarity rather than extensive lipophilic tissue accumulation
D) Ethosuximide has a volume of distribution of approximately 15 to 20 L/kg, similar to highly lipophilic drugs such as chlorpromazine, because ethosuximide's succinimide ring structure confers high lipid solubility and extensive CNS and adipose tissue binding
E) Ethosuximide has a volume of distribution of approximately 0.3 L/kg, confined to the extracellular fluid space, because its molecular weight exceeds the threshold for free glomerular filtration and its charged succinimide nitrogen prevents passive membrane crossing
ANSWER: C
Rationale:
Ethosuximide has a volume of distribution of approximately 0.7 L/kg, which corresponds closely to total body water (approximately 0.6 L/kg in adults). This value reflects ethosuximide's pharmacochemical profile: low protein binding (less than 10%) and moderate polarity that allows distribution throughout body water without extensive lipophilic sequestration into adipose tissue or other deep compartments. A volume of distribution near total body water means that drug concentrations in plasma, CSF, and other aqueous compartments are similar, which is consistent with ethosuximide's good CNS penetration and explains why total plasma concentration reliably reflects pharmacologically active free drug — a key feature supporting therapeutic drug monitoring.
Option A: Option A is incorrect because a volume of distribution of 0.1 L/kg would indicate near-complete confinement to plasma, which is characteristic of highly protein-bound drugs with limited tissue penetration such as certain penicillins; ethosuximide distributes throughout total body water at approximately 0.7 L/kg and does not have high protein binding.
Option B: Option B is incorrect because a volume of distribution of 5 to 10 L/kg would indicate extensive lipophilic tissue accumulation far beyond plasma and interstitial fluid; ethosuximide's volume of approximately 0.7 L/kg confirms it does not undergo this degree of tissue sequestration.
Option D: Option D is incorrect because 15 to 20 L/kg is characteristic of highly lipophilic drugs with extensive tissue binding such as certain antipsychotics and tricyclic antidepressants; ethosuximide's succinimide structure does not confer this degree of lipid solubility, and its actual volume of distribution of approximately 0.7 L/kg is far lower.
Option E: Option E is incorrect because 0.3 L/kg would restrict ethosuximide to extracellular fluid, which would impair CNS penetration and be inconsistent with its clinical efficacy; ethosuximide distributes throughout total body water at approximately 0.7 L/kg, achieving good CNS tissue concentrations.
12. A patient on brivaracetam develops stage 3 chronic kidney disease (CrCl 35 mL/min). The treating neurologist asks whether the brivaracetam dose requires adjustment. Which response correctly addresses both the dose adjustment question and the protein binding characteristic relevant to this scenario?
A) Brivaracetam dose must be reduced in this patient because it is approximately 85% protein-bound, and reduced renal elimination of protein-binding competitors in CKD increases free brivaracetam concentrations to potentially toxic levels even without changing total drug concentrations
B) Brivaracetam dose must be reduced because it is renally eliminated unchanged, like levetiracetam; patients with CrCl below 50 mL/min require a 50% dose reduction to prevent accumulation of parent drug and its active metabolites
C) Brivaracetam dose does not require adjustment in renal impairment, but its high protein binding of approximately 80% means that hypoalbuminemia from CKD-related nephrotic syndrome could meaningfully increase free drug exposure and should be monitored
D) Brivaracetam dose requires adjustment only when CrCl falls below 15 mL/min (stage 5 CKD), because small amounts of brivaracetam and its carboxylic acid metabolite are renally excreted and can accumulate at very low glomerular filtration rates
E) Brivaracetam does not require dose adjustment for renal impairment because it undergoes hepatic metabolism rather than renal elimination; its protein binding is approximately 17% (low), so hypoalbuminemia from CKD is also not a significant concern for free drug accumulation
ANSWER: E
Rationale:
Brivaracetam undergoes hepatic metabolism as its primary elimination pathway — primarily amidase-mediated hydrolysis to an inactive carboxylic acid, with a minor CYP2C19 contribution — and does not require dose adjustment for renal impairment. This distinguishes it from levetiracetam, which is renally eliminated unchanged and requires dose reduction when CrCl falls below 50 mL/min. Brivaracetam's protein binding is approximately 17%, which is low; at this binding level, changes in plasma albumin concentration (as occur in nephrotic syndrome or malnutrition complicating CKD) have minimal impact on free drug exposure. Both of these pharmacokinetic properties — hepatic rather than renal elimination, and low protein binding — mean that this patient's CKD does not trigger a brivaracetam dose adjustment. Dose adjustment is required in moderate to severe hepatic impairment (Child-Pugh B or C).
Option A: Option A is incorrect because brivaracetam's protein binding is approximately 17%, not 85%; high protein binding with renal accumulation of displacement competitors is a concern for drugs such as phenytoin (approximately 90% bound) or valproate in advanced CKD, not brivaracetam.
Option B: Option B is incorrect because brivaracetam is not renally eliminated unchanged; unlike levetiracetam, it undergoes hepatic metabolism and does not follow the same renal dose-adjustment schedule.
Option C: Option C is incorrect because brivaracetam's protein binding is approximately 17%, not 80%; at 17% binding, changes in albumin from nephrotic syndrome would have negligible effects on free drug fraction. The statement's premise about protein binding is factually wrong.
Option D: Option D is incorrect because the established clinical guidance for brivaracetam does not require dose adjustment for any stage of renal impairment short of dialysis considerations; the primary dose-adjustment criterion is hepatic impairment, not renal impairment at any CrCl threshold.
13. The C017 pivotal trial of cenobamate reported seizure-freedom rates during the 12-week maintenance period. Which values correctly state the seizure-freedom rates for the cenobamate 200 mg/day group and the placebo group in the C017 trial?
A) In the C017 trial, approximately 21% of patients receiving cenobamate 200 mg/day achieved complete seizure freedom during the 12-week maintenance period, compared with approximately 1% of patients receiving placebo
B) In the C017 trial, approximately 40% of patients receiving cenobamate 200 mg/day achieved complete seizure freedom, compared with approximately 8% of patients receiving placebo — a difference that placed cenobamate within the range of typical anti-seizure drugs for drug-resistant epilepsy
C) In the C017 trial, approximately 10% of patients receiving cenobamate 200 mg/day achieved complete seizure freedom, compared with approximately 3% of patients receiving placebo — a modest but statistically significant difference consistent with results from other approved adjunctive anti-seizure drugs
D) In the C017 trial, approximately 55% of patients receiving cenobamate 200 mg/day achieved complete seizure freedom, compared with approximately 5% of patients receiving placebo — the highest seizure-freedom rate ever reported for any adjunctive anti-seizure drug in a randomized controlled trial
E) In the C017 trial, approximately 21% of patients receiving cenobamate 200 mg/day achieved a 50% or greater reduction in seizure frequency (the 50% responder rate), compared with approximately 1% of patients receiving placebo — the same benchmark used for all other approved anti-seizure drugs in this population
ANSWER: A
Rationale:
In the pivotal C017 trial, cenobamate 200 mg/day produced complete seizure freedom in approximately 21% of patients during the 12-week maintenance period, compared with approximately 1% for placebo. This seizure-freedom rate — not a responder rate or median reduction figure, but complete seizure freedom — was the primary finding that distinguished cenobamate from prior approved anti-seizure drugs in drug-resistant focal epilepsy, where historical seizure-freedom rates had been approximately 3 to 8%. The 21% figure represents roughly 3 to 7 times the seizure-freedom rate seen with other approved adjunctive agents in similar populations, which is why the C017 data generated substantial clinical interest. The 400 mg/day group also showed approximately 28% seizure freedom in the same trial.
Option B: Option B is incorrect because the seizure-freedom rate for cenobamate 200 mg/day was approximately 21%, not 40%, and the placebo rate was approximately 1%, not 8%; a placebo rate of 8% would be unusually high for a drug-resistant epilepsy trial and would substantially understate the treatment effect.
Option C: Option C is incorrect because a 10% seizure-freedom rate at 200 mg/day would not distinguish cenobamate from prior agents — the 3 to 8% historical range means a 10% rate would represent only a modest incremental improvement, not the striking efficacy finding that cenobamate's clinical program actually demonstrated.
Option D: Option D is incorrect because approximately 55% seizure freedom is not the figure reported for the 200 mg/day group; the 55% figure reported in C017 corresponds to median seizure frequency reduction, not seizure-freedom rate.
Option E: Option E is incorrect because the 21% figure refers to complete seizure freedom, not to the 50% responder rate; conflating these two endpoints misrepresents the nature of cenobamate's efficacy signal and is a clinically important distinction.
14. Perampanel carries distinct FDA-approved age thresholds for its two seizure-type indications. Which statement correctly identifies both approved indications and their respective minimum age requirements?
A) Perampanel is approved for adjunctive treatment of focal onset seizures in patients aged 12 years and older, and for adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 18 years and older, reflecting the more conservative regulatory approach for the generalized epilepsy indication
B) Perampanel is approved for adjunctive treatment of focal onset seizures in patients aged 4 years and older, and for adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older
C) Perampanel is approved for adjunctive treatment of focal onset seizures in patients aged 2 years and older, and for adjunctive treatment of all generalized seizure types including absence and myoclonic seizures in patients aged 4 years and older
D) Perampanel is approved for adjunctive treatment of focal onset seizures and primary generalized tonic-clonic seizures in patients aged 12 years and older for both indications, with the same age threshold applied uniformly across seizure types
E) Perampanel is approved as monotherapy (not adjunctive) for focal onset seizures in patients aged 4 years and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 years and older, reflecting its established efficacy as a first-line agent for focal epilepsy
ANSWER: B
Rationale:
Perampanel has two FDA-approved indications with different minimum age requirements: adjunctive treatment of focal onset seizures in patients aged 4 years and older, and adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients aged 12 years and older. The lower age threshold for the focal seizure indication (4 years) reflects earlier completion of pediatric clinical trials for that indication, while the PGTC indication required separate clinical demonstration of efficacy in the generalized epilepsy population, which was evaluated in older patients. These age thresholds are clinically relevant when considering perampanel for pediatric patients with either seizure type.
Option A: Option A is incorrect because the minimum age for the focal onset seizure indication is 4 years, not 12 years; the 12-year minimum applies to the PGTC indication.
Option C: Option C is incorrect because perampanel's minimum age for focal onset seizures is 4 years, not 2 years, and perampanel is not approved for absence or myoclonic seizures — only for focal onset and primary generalized tonic-clonic seizures. Absence and myoclonic seizure types are not part of perampanel's approved indications.
Option D: Option D is incorrect because the two indications do not share the same 12-year age threshold; the focal onset seizure indication has a lower minimum age of 4 years, and using 12 years for both would incorrectly exclude eligible pediatric patients aged 4 to 11 from the focal seizure indication.
Option E: Option E is incorrect because perampanel is approved as adjunctive therapy for focal onset seizures, not as monotherapy; the statement's characterization of perampanel as a first-line monotherapy agent misrepresents its regulatory approval status.
15. Gabapentin's bioavailability is dose-dependent in a clinically important way. Which values correctly describe gabapentin's bioavailability at low versus high doses, and what mechanism produces this dose-dependency?
A) Gabapentin's bioavailability is approximately 95% at low doses and falls to approximately 70% at high doses, due to saturation of hepatic first-pass CYP3A4 metabolism that paradoxically reduces the formation of an active metabolite required for full absorption
B) Gabapentin's bioavailability is approximately 80% at low doses and falls to approximately 60% at high doses due to saturation of intestinal P-glycoprotein-mediated active transport that normally facilitates gabapentin uptake from the intestinal lumen into enterocytes
C) Gabapentin's bioavailability is approximately 60% at low doses and remains stable at approximately 55 to 60% across all doses because the absorptive transporter, while saturable in vitro, operates below its saturation threshold throughout the clinically used dose range
D) Gabapentin's bioavailability is approximately 60% at low doses and falls to less than 35% at high doses because it is absorbed via a saturable transporter in the small intestine; as dose increases, the transporter becomes progressively saturated and a smaller fraction of each dose is absorbed
E) Gabapentin's bioavailability is approximately 35% at low doses and rises to approximately 75% at high doses through autoinduction of the intestinal transporter responsible for its absorption, a process that takes approximately 2 to 3 weeks to reach maximum induction
ANSWER: D
Rationale:
Gabapentin absorption depends on a saturable amino acid transporter in the small intestinal mucosa. At low doses, the transporter operates below saturation and approximately 60% of each dose is absorbed. As dose increases, the transporter becomes progressively saturated, reducing the fraction absorbed per dose. At high doses, bioavailability can fall below 35%. This non-linear relationship means that dose increases do not produce proportional increases in plasma concentration — a clinically important characteristic that complicates dose titration at higher doses and distinguishes gabapentin from pregabalin, which has linear absorption exceeding 90% across its full dose range via the same transporter type but with different saturation kinetics. Dividing gabapentin doses (e.g., three-times-daily rather than once-daily) can improve total daily absorption by presenting smaller individual amounts to the transporter per interval.
Option A: Option A is incorrect because gabapentin does not undergo hepatic first-pass metabolism; it is eliminated renally unchanged with no significant hepatic metabolic pathway. The premise of CYP3A4-mediated first-pass reducing an active metabolite is pharmacologically incorrect for gabapentin.
Option B: Option B is incorrect because the transporter responsible for gabapentin absorption is an amino acid carrier in the intestinal mucosa, not P-glycoprotein; P-gp is an efflux transporter, not an absorptive carrier, and its saturation would impair efflux (increasing absorption), not reduce it.
Option C: Option C is incorrect because gabapentin's absorptive transporter does saturate within the clinically used dose range; the non-linear pharmacokinetics are a well-documented clinical pharmacokinetic characteristic that has real consequences for dose-response prediction, particularly at doses above 1800 mg/day.
Option E: Option E is incorrect because gabapentin's bioavailability falls rather than rises with increasing dose, and the mechanism is transporter saturation (a pharmacokinetic limitation), not autoinduction of an absorptive pathway; autoinduction as a cause of increasing bioavailability at higher doses is not an established mechanism for gabapentin.
16. Federal and state controlled substance scheduling for gabapentin and pregabalin differs and has prescribing implications. Which statement correctly describes the controlled substance status of each drug in the United States?
A) Both pregabalin and gabapentin are Schedule II controlled substances federally because their abuse potential in combination with opioids produces respiratory depression equivalent to that seen with opioid monotherapy, placing them in the same regulatory category as oxycodone and fentanyl
B) Pregabalin is a Schedule IV controlled substance federally, and gabapentin is a Schedule V controlled substance federally; the difference in scheduling reflects pregabalin's higher abuse potential and greater capacity to produce euphoria compared to gabapentin
C) Pregabalin is a Schedule V controlled substance under federal law; gabapentin is not a federally scheduled controlled substance, though it has been designated Schedule V in several individual states due to recognized abuse potential, particularly in patients with opioid use disorder
D) Neither pregabalin nor gabapentin is a controlled substance under federal law; both were removed from Schedule V classification in 2022 after post-marketing surveillance indicated that abuse rates did not meet the statutory threshold for scheduled substance classification
E) Gabapentin is a Schedule V controlled substance federally, while pregabalin is unscheduled federally; this reflects gabapentin's earlier approval and greater established abuse history compared to pregabalin, which was exempted from federal scheduling due to its more restricted prescribing indications
ANSWER: C
Rationale:
Pregabalin is classified as a Schedule V controlled substance under federal law in the United States, reflecting its recognized abuse potential — particularly in patients with opioid use disorder, where concurrent use can produce enhanced sedation and euphoria, and where respiratory depression risk with concurrent opioids is increased. Gabapentin is not federally scheduled as a controlled substance, but its abuse potential is recognized; a growing number of individual states have designated gabapentin as a Schedule V controlled substance at the state level, requiring prescriptions, reporting to prescription drug monitoring programs (PDMPs), and other regulatory controls. This regulatory difference has practical prescribing implications: pregabalin prescriptions require controlled substance tracking federally, while gabapentin requirements vary by state.
Option A: Option A is incorrect because neither gabapentin nor pregabalin is a Schedule II controlled substance; Schedule II is reserved for substances with high abuse potential and severe dependence risk such as opioids, stimulants, and cocaine. Alpha-2-delta agents are Schedule V at most, reflecting lower but recognized abuse potential.
Option B: Option B is incorrect because pregabalin is Schedule V, not Schedule IV; Schedule IV includes benzodiazepines and zolpidem. The relative scheduling reversal stated in this option is also wrong — pregabalin is Schedule V federally, while gabapentin is not federally scheduled at all.
Option D: Option D is incorrect because pregabalin remains a Schedule V controlled substance under federal law as of current regulatory status; it has not been removed from scheduling, and the premise of a 2022 descheduling based on post-marketing surveillance is factually incorrect.
Option E: Option E is incorrect because the scheduling status is reversed in this option — it is pregabalin that is federally scheduled (Schedule V), not gabapentin; gabapentin is the agent with state-level scheduling in some jurisdictions rather than federal scheduling.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.